Open Journal Systems
Neuropsychiatric adverse effects of psychotropic agents: a review
Abstract
A psychotropic agent is any drug that is likely to affect the behaviour, mood, thoughts, or perception. They are used for the treatment of psychiatric illnesses. These drugs sometimes pose a threat of adverse events. Some of these adverse events are neuropsychiatric, which are generally hard to diagnose because of the already existing illness. The spectrum can range from a variety of symptoms like episodes of seizure to acute psychosis. The article emphasizes the frequency of such adverse events and means to raise awareness among medical practitioners regarding the same. The various neuropsychiatric adverse effects and the agents responsible have been reviewed, along with their possible mechanisms and general management.
The information for writing this review was selected by searching for keywords such as Neuropsychiatry, Antidepressants, Psychosis and neurotoxicity in databases such as Google Scholar and PubMed. Post searching the articles in the above-mentioned databases, they were screened concerning their importance with our work and according to their title and abstract. Additional articles were discovered by checking the references in the current study's citations. Using this method, the various neuropsychiatric adverse effects of psychotropic agents were summarized in this review.
References
Salma Malik, MD, MS, Robert Sahl, MD, Khalid Elzamzamy, MBBCh, Monica Nakhla, DO and Muhammad Waqar Azeem, MD. Neurological Side Effects of Psychotropic Medications. Psychiatric annals. September 01, 2021. Vol. 51, No. 9.
T. S. Sathyanarayana Rao and Chittaranjan Andrade. Classification of psychotropic drugs: Problems, solutions, and more problems. Indian J Psychiatry. 2016 Apr-Jun; 58(2): 111–113.
J van Os 1, T Fahy, P Jones, I Harvey, B Toone, R Murray. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand. 1997 Sep;96(3):206-16
Francesco Pisani 1, Giancarla Oteri, Cinzia Costa, Giorgio Di Raimondo, Raoul Di Perri. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002;25(2):91-110.
Katrin Sangkuhl, Teri Klein, and Russ Altman. Selective Serotonin Reuptake Inhibitors (SSRI) Pathway. Pharmacogenet Genomics. 2009 Nov; 19(11): 907–909.
Francescangeli J, Karamchandani K, Powell M, Bonavia A. The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2019 May 09;20(9)
Peter M Haddad 1, Serdar M Dursun. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008 Jan;23 Suppl 1:15-26.
Kelly C Lee 1, Patrick R Finley, Brian K Alldredge. Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings. Expert Opin Drug Saf. 2003 May;2(3):233-47.
Muhammad Bhatti, Parshaw Dorriz, Prachi Mehndiratta. Impact of Psychotropic drugs on Seizure threshold (P6.311). April 18, 2017; 88
Dawson Hedges 1, Kreg Jeppson, Paul Whitehead. Antipsychotic medication and seizures: a review. Drugs Today (Barc).2003 Jul;39(7):551-7
D'Souza RS, Mercogliano C, Ojukwu E, D'Souza S, Singles A, Modi J, Short A, Donato A. Effects of prophylactic anticholinergic medications to decrease extrapyramidal side effects in patients taking acute antiemetic drugs: a systematic review and meta-analysis. Emerg Med J. 2018 May;35(5):325-331
Rifkin A. Extrapyramidal side effects: a historical perspective. J Clin Psychiatry. 1987 Sep;48 Suppl:3-6.
Peng Li,* Gretchen L. Snyder, and Kimberly E. Vanover. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past,Present and Future. Curr Top Med Chem. 2016 Dec; 16(29): 3385–3403.
Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: A review of the evidence. Eur J Epidemiol. 2011;26 Suppl 1:S1–58.
Hae-Won Shina and Sun Ju Chung Drug-Induced Parkinsonism. J Clin Neurol v.8(1); 2012 Mar
Peter N van Harten, director, psychiatric residency programme,a Hans W Hoek, associate professor,b and Rene S Kahn, chairmanc. Acute dystonia induced by drug treatment. v.319(7210); 1999 Sep 4
Hanna Bergman, Paranthaman S Bhoopathi, Karla Soares‐Weiser, and Cochrane Schizophrenia Group. Benzodiazepines for antipsychotic‐induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan; 2018(1): CD000205.
Haitham Salem,a,b Caesa Nagpal,b Teresa Pigott,b and Antonio Lucio Teixeiraa,b,*. Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges. Curr Neuropharmacol. 2017 Jul; 15(5): 789–798
Thomas RE Barnes, Karla Soares‐Weiser, Josué Bacaltchuk, and Cochrane Schizophrenia Group. Central action beta‐blockers versus placebo for neuroleptic‐induced acute akathisia. Cochrane Database Syst Rev. 2004 Oct; 2004(4): CD001946.
Olga Waln and Joseph Jankovic. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov (N Y). 2013; 3: tre-03-161-4138-1.
P S Sachdev. The current status of tardive dyskinesia. Aust N Z J Psychiatry. 2000 Jun;34(3):355-69.
Navneet Kaur,a Puneet Kumar,a,* Sumit Jamwal,a Rahul Deshmukh,a and Vinod Gauttamb. Tetrabenazine: Spotlight on Drug Review. Ann Neurosci. 2016 Sep; 23(3): 176–185.
Lucia Ricciardi,1 Tamara Pringsheim,2 Thomas R.E. Barnes,3 Davide Martino,4 David Gardner,5 Gary Remington,6 Donald Addington,7 Francesca Morgante,1 Norman Poole,8 Alan Carson,9 and Mark Edwards1 . Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019 Jun; 64(6): 388–399.
T. Scott Stroup 1 and Neil Gray 2 . Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018 Oct; 17(3): 341–356.
Stefan Leucht 1, Kristian Wahlbeck, Johannes Hamann, Werner Kissling. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003 May 10;361(9369):1581-9.
Jian-Ping Zhang, MD, PhD,1 Juan A. Gallego, MD,1,2 Delbert G. Robinson, MD,1,3,4 Anil K. Malhotra, MD,1,2,3,4 John M. Kane, MD,1,2,3,4 and Christoph U. Correll, MD1,2,3,4. Efficacy and Safety of Individual Second-Generation vs First-Generation Antipsychotics in First Episode Psychosis: A Systematic Review and Meta-analysis. Int J Neuropsychopharmacol. 2013 Jul; 16(6): 1205–1218.
Brian D. Berman, MD, MS1. Neuroleptic Malignant Syndrome. Neurohospitalist. 2011 Jan; 1(1): 41–47.
Lurdes Tse,1 Alasdair M. Barr,1,2 Vanessa Scarapicchia,2,3 and Fidel Vila-Rodriguez2,3,*. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Curr Neuropharmacol. 2015 May; 13(3): 395–406.
Van Rensburg R, Decloedt EH. An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome. Psychopharmacol Bull. 2019 Feb 15;49(1):84-91
Julie Langan, Daniel Martin, Polash Shajahan & Daniel J Smith. Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report. BMC Psychiatry volume 12, Article number: 214 (2012)
P Sakkas 1, J M Davis, P G Janicak, Z Y Wang. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 1991;27(3):381-4.
Federica Luchini, Pierpaolo Medda, Michela Giorgi Mariani, Mauro Mauri, Cristina Toni, and Giulio Perugi. Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World J Psychiatry. 2015 Jun 22; 5(2): 182–192.
Adam Wichniak, 1,2 Aleksandra Wierzbicka,2 Małgorzata Walęcka,1 and Wojciech Jernajczyk2.. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017; 19(9): 63.
de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25.
Luc Staner, MD*,Sleep disturbances, psychiatric disorders, and psychotropic drugs, Dialogues Clin Neurosci. 2005 Dec; 7(4): 323–334.
Michael Liebowitz, Harry A. Croft, Daniel K. Kajdasz, Heidi Whalen, Susan Gallipoli, Maria Athanasiou, and Carol R. Reed. The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder, Psychopharmacol Bull. 2011 Sep 15; 44(3): 15–33.
Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000 Apr;58(1):19-36.
Culpepper L. Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy. Prim Care Companion CNS Disord. 2013;15(5)
Karl Doghramji 1, William C Jangro 2. Adverse Effects of Psychotropic Medications on Sleep. Sleep Med Clin 2016 Dec;11(4):503-514
Sang Heon Lee,1 Wan Seok Seo, 1 Hyung Mo Sung,2 Tae Young Choi,3 So Yeun Kim,1 So-Jeong Choi,1 Bon Hoon Koo,1 and Jong Hun Lee3. Effect of Methylphenidate on Sleep Parameters in Children with ADHD. Psychiatry Investig. 2012 Dec; 9(4): 384–390.
Email this article 
